Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Completed · Phase 3 · Has a placebo group

Conditions studied: Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV

In brief

Rationale: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than a placebo as maintenance therapy in treatment of subjects with non-small cell lung cancer. Purpose: This randomized phase III trial is studying vaccine therapy to see how well it works compared with a placebo in treating subjects with stage III or stage IV non-small cell lung cancer.

Key facts

Study ID

NCT00676507

Run by

NovaRx Corporation

People needed

532

Starts

2008-07-01

Expected to finish

2013-01-01

Last updated by the study team

2015-05-08

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with histologically or cytologically confirmed NSCLC who meet one of the following staging requirements:
• Stage IIIA (T3N2 only) or
• Stage IIIB or
• Stage IV.
• Subjects must have stable disease (SD) or an objective response (PR or CR) to a prior single, frontline, platinum-based chemotherapy regimen (additional prior adjuvant chemotherapy is permitted) consisting of up to six (6) treatment cycles with or without concomitant radiation therapy.
• Not less than four weeks nor more than four months must have elapsed since the completion of the last chemotherapy cycle and registration into the study.
• Subjects treated for brain metastasis(es) are eligible if they have been stable for ≥ 2 months.
• Signed informed consent.
• Not less than 18 years and not more than 75 years old.
• Estimated life expectancy of at least 12 weeks.
• Performance status (ECOG) ≤ 2.
• Absolute neutrophil count ≥ 1,500/mm3.
• Hemoglobin ≥ 9 g/dL.
• Platelet count ≥ 100,000/mm3.
• Albumin levels ≥ 2.5 g/dL.
• Bilirubin ≤ 1.5 times the upper limit of normal (ULN).
• Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 1.5 × ULN.
• Creatinine ≤ 1.5 × ULN.
• Alkaline phosphatase ≤ 5 × ULN.

You may not qualify if…

• Concurrent systemic steroids > 2 mg /day prednisone (or prednisone-equivalent of prednisolone or dexamethasone).
• Prior splenectomy.
• Any surgery involving general anesthesia < 4 weeks prior to study registration.
• Chemotherapy more than 4 months or less than 4 weeks prior to study registration.
• Steroid therapy (excluding ≤ 2 mg/day prednisone or prednisone-equivalent of prednisolone or dexamethasone), radiation therapy, or immunotherapy less than 4 weeks prior to study registration.
• Subjects with documented active brain metastasis(es) at the time of study entry are ineligible. However, subjects treated for brain metastasis(es) are eligible if they have been stable for ≥ 2 months.
• Painful bone metastases, or bone metastases that require immediate therapy.
• Significant and/or symptomatic pleural effusions. Presence of clinically detectable (by physical exam) third-space fluid collections, for example, pleural effusions that cannot be controlled by previous chemotherapy and/or drainage, or other procedures, prior to study entry.
• Known allergies to eggs or soy.
• Significant weight loss (≥ 10% body weight in preceding 6 weeks).
• Known HIV positivity (EBV origin of replication in the pCHEK/HBA2 vector used to modify the vaccine components can trans-activate HIV).
• Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections) or other conditions that, in the opinion of the investigator, would compromise study objectives.
• NCI CTC Grade 3 or 4 peripheral neuropathy at study registration.
• Prior other malignancies (excluding non-melanoma carcinomas of the skin) unless in remission for ≥ 2 years.
• History of psychiatric disorder that would impede ability to give informed consent or adherence to study requirements.
• Pregnant or nursing women, or refusal to practice contraception if of reproductive potential.
• Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
• Known active Epstein-Barr infection within ≤ 60 days of study registration.

Where it is running

• Alaska Regional Hospital — Anchorage, Alaska, United States
• Mayo Clinic Cancer Center — Scottsdale, Arizona, United States
• Clopton Clinic Hematology/Oncology — Jonesboro, Arkansas, United States
• Comprehensive Blood and Cancer Center — Bakersfield, California, United States
• University of California, San Diego — La Jolla, California, United States
• UCLA Pasadena Oncology — Pasadena, California, United States
• Cancer Care Associates — Redondo, California, United States
• Innovative Research Center of California — San Diego, California, United States
• Sansum Clinic — Santa Barbara, California, United States
• Santa Barbara Hematology Oncology Medical Group, Inc. — Santa Barbara, California, United States
• Central Coast Medical Oncology Corporation — Santa Maria, California, United States
• UCLA Cancer Center — Santa Monica, California, United States
• UCLA Cancer Center-Valencia — Valencia, California, United States
• UCLA Cancer Center — Westlake Village, California, United States
• University of Colorado Health Science Center — Aurora, Colorado, United States
• Pasco Hernando Oncology Associates, P.A. — Brooksville, Florida, United States
• Medical Specialist of Palm Beaches — Lake Worth, Florida, United States
• Ocala Oncology — Ocala, Florida, United States
• Space Coast Medical Center — Titusville, Florida, United States
• Atlanta Cancer Care — Roswell, Georgia, United States
• Kootenai Cancer Center — Coeur d'Alene, Idaho, United States
• St. Francis Medical Group Oncology and Hematology Specialists — Indianapolis, Indiana, United States
• Iowa Blood and Cancer Center — Cedar Rapids, Iowa, United States
• James Graham Brown Cancer Center — Louisville, Kentucky, United States
• Southern Cancer Center — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.